Effectiveness of Mammography Screening on Breast Cancer Mortality – A Study Protocol for Emulation of Target Trials Using German Health Claims Data

References

• Biesheuvel C, Weigel S, Heindel W. Mammography screening: evidence, history and current practice in Germany and other European countries. Breast Care. 2011;6(2):104–109. doi:10.1159/000327493
   Web of Science ®Google Scholar
• John S, Broggio J Cancer survival in England: national estimates for patients followed up to 2017. Newport: Office for National Statistics; 2019.
   Google Scholar
• Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106(3):416–422. doi:10.1002/ijc.11226
   PubMed Web of Science ®Google Scholar
• Erdmann F, Spix C, Katalinic A, et al. Krebs in Deutschland für 2017/2018; 2021. Available from: https://edocrkide/handle/176904/9042. Accessed August 24, 2022.
   Google Scholar
• Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016;164(4):244–255. doi:10.7326/M15-0969
   PubMed Web of Science ®Google Scholar
• Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–2240. doi:10.1038/bjc.2013.177
   PubMed Web of Science ®Google Scholar
• Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S149–S161. doi:10.1007/s00259-004-1538-5
   Web of Science ®Google Scholar
• Jansen L, Holleczek B, Kraywinkel K, et al. Divergent patterns and trends in breast cancer incidence, mortality and survival among older women in Germany and the United States. Cancers. 2020;12(9):2419. doi:10.3390/cancers12092419
   Web of Science ®Google Scholar
• Chiarelli AM, Edwards SA, Prummel MV, et al. Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program. Radiology. 2013;268(3):684–693. doi:10.1148/radiol.13122567
   Web of Science ®Google Scholar
• Duffy SW, Tabar L, Yen AM, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126(13):2971–2979. doi:10.1002/cncr.32859
   PubMed Web of Science ®Google Scholar
• Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014;106(11). doi:10.1093/jnci/dju261
   Google Scholar
• Lauby-Secretan B, Loomis D, Straif K. Breast-cancer screening - viewpoint of the IARC working group. N Engl J Med. 2015;373(15):1479. doi:10.1056/NEJMc1508733
   Google Scholar
• Kääb-Sanyal V, Hand E. Jahresbericht evaluation 2019 deutsches mammographie-screening-programm. Kooperationsgemeinschaft Mammographie; 2021.
   Google Scholar
• Schmuker C, Zok K. Informierte Teilnahme an Früherkennungsuntersuchungen: Ergebnisse einer Befragung unter GKV-Versicherten [Informed participation in screening examinations: Results of a survey among individuals enrolled in statutory health insurance]. Versorgungsreport Früherkennung. 2019:31–78. doi:10.32745/9783954664023-2
   Google Scholar
• Young JG, Stensrud MJ, Tchetgen EJT, Hernan MA. A causal framework for classical statistical estimands in failure-time settings with competing events. Stat Med. 2020;39(8):1199–1236. doi:10.1002/sim.8471
   Web of Science ®Google Scholar
• Haug U, Schink T. German pharmacoepidemiological research database (GePaRD). In: Sturkenboom M, Schink T, editors. Databases for Pharmacoepidemiological Research. Springer; 2021:119–124.
   Google Scholar
• Czwikla J, Urbschat I, Kieschke J, Schussler F, Langner I, Hoffmann F. Assessing and explaining geographic variations in mammography screening participation and breast cancer incidence. Front Oncol. 2019;9:909. doi:10.3389/fonc.2019.00909
   Web of Science ®Google Scholar
• Busse R, Blumel M, Knieps F, Barnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet. 2017;390(10097):882–897. doi:10.1016/S0140-6736(17)31280-1
   PubMed Web of Science ®Google Scholar
• Hernan MA, Robins JM. Causal Inference - What if. Chapman & Hall/CRC; 2020.
   Google Scholar
• Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764. doi:10.1093/aje/kwv254
   PubMed Web of Science ®Google Scholar
• Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–75. doi:10.1016/j.jclinepi.2016.04.014
   PubMed Web of Science ®Google Scholar
• Garcia-Albeniz X, Hsu J, Hernan MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. Eur J Epidemiol. 2017;32(6):495–500. doi:10.1007/s10654-017-0287-2
   PubMed Web of Science ®Google Scholar
• Zhao SS, Lyu H, Yoshida K. Versatility of the clone-censor-weight approach: response to “trial emulation in the presence of immortal-time bias”. Int J Epidemiol. 2021;50(2):694–695. doi:10.1093/ije/dyaa223
   Web of Science ®Google Scholar
• Maringe C, Benitez Majano S, Exarchakou A, et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol. 2020;49(5):1719–1729. doi:10.1093/ije/dyaa057
   Web of Science ®Google Scholar
• Joffe MM. Administrative and artificial censoring in censored regression models. Stat Med. 2001;20(15):2287–2304. doi:10.1002/sim.850
   PubMed Web of Science ®Google Scholar
• Robins JM, Hernan MÁ, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–560. doi:10.1097/00001648-200009000-00011
   PubMed Web of Science ®Google Scholar
• Langner I, Ohlmeier C, Haug U, Hense HW, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: a validation study based on a record linkage with administrative mortality data. BMJ Open. 2019;9(7):e026834. doi:10.1136/bmjopen-2018-026834
   Web of Science ®Google Scholar
• Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17(3):215–223. doi:10.1002/pds.1545
   Web of Science ®Google Scholar
• Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601–1606. doi:10.1038/s41591-019-0597-x
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10Supl 2):S131–S42. doi:10.1097/MLR.0b013e318070c08e
   Web of Science ®Google Scholar
• Garcia-Albeniz X, Hernan MA, Hsu J. Continuation of annual screening mammography and breast cancer mortality in women older than 70 years. Ann Intern Med. 2020;173(3):247. doi:10.7326/L20-0827
   Web of Science ®Google Scholar
• Groenwold RHH. Trial emulation and real-world evidence. JAMA Netw Open. 2021;4(3):e213845. doi:10.1001/jamanetworkopen.2021.3845
   Web of Science ®Google Scholar
• Loberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17:63. doi:10.1186/s13058-015-0525-z
   PubMed Web of Science ®Google Scholar
• Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ. 2013;346:f385. doi:10.1136/bmj.f385
   PubMed Web of Science ®Google Scholar
• Herrmann C, Vounatsou P, Thurlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open. 2018;8(3):e017806. doi:10.1136/bmjopen-2017-017806
   Web of Science ®Google Scholar
• Biller-Andorno N, Juni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014;370(21):1965–1967. doi:10.1056/NEJMp1401875
   Web of Science ®Google Scholar
• Lee CI, Etzioni R. Missteps in current estimates of cancer overdiagnosis. Acad Radiol. 2017;24(2):226–229. doi:10.1016/j.acra.2016.05.020
   Web of Science ®Google Scholar